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Introduction
plasmatic NPY concentration has also been reported' 13141 . _ ..
. , ,. . . . , , For these reasons, the chronic increase in both NPY and Cardiac mechanical function is mainly regulated by the nore ine hine concentrations could lead to a potentially autonomic nervous system, and recently it has been deleterious action on ventricular function . ^ present shown that the heart is innervated by pept.derg.c neurons stud was ^ ^ tQ ^^ M baseli jn jems wkh that may act as neurotransmitters or as neuromodula-stab , e c tive heart fail , asma nore pi n e P hrine tors"; 5 !. Neuropeptide Y (NPY), originally isolated from and Npy concentrations ^^ in the femora i art and in porcine brains^ has been demonstrated to coexist both ^ corQ smus and tQ examjne thdr relationshi to with norep.nephnne, >n peripheral sympathetic nerves haemod ic pararne t e rs. Furthermore, concentration and with epinephnne, in the adrenal medulla' 7 -10 !. ^ nephrine and NPY were assessed during NPY-hke immune-reactivity has been found in nerves aninotropicinterventionwhichdecreasedt he sympathetic within the myocardium and around cardiac blood vessels, tone lisi suggesting that this peptide could participate in inotropic and chronotropic responses and may be an important regulator of coronary vasomotor tone 1 ' 1 . Indeed, this Methods peptide's potent vasoconstrictor effect and a potent PATIENTS inhibiting cardiac contractility has been demonstrated in Sixteen men and two women (age; 46 ± , 5 years) in animal studies' 91112 '. A potent vasoconstrictor action on functiona i New York Heart Association class II or III, coronary vessels has also been reported in humans" 2 '. In with djlated cardiomyopathy, as documented by echopatients with congestive heart failure (CHF), a high circu-cartography and previous episodes of congestive heart lating norepinephrine concentration reflecting chronic failure> participated in this study. Idiopathic dilated sympathetic system hyperactivity has been demonstrated, cardiomyopathy was the cause of congestive heart failure, In these patients, when compared to controls, a higher a ,, patients were in sinus rhythm and had had a pre vious Submitted for publication on 22 
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Cl= cardiac index; LVEDP = left ventricular end-diastolic pressure, MAP = mean aortic blood pressure; SV R = systolic vascular resistance, H R = heart rate; dP . dt"' = peak positive left ventricular dP . dt '. Results are expressed as mean ± standard deviation.
BASELINE HAEMODYNAMIC PARAMETERS
Patients fasted for at least 12 h before the procedure, which involved recording the following haemodynamic parameters during right (Swan-Ganz thermodilution catheter: Edwards Laboratory, Irvine, California) and left catheterization (5 Fr micromanometer-tipper catheter; Millar Industries, Houston, TX, U.S.A.): mean right atrial pressure, LV end-diastolic and systolic pressures, the first derivative of LV pressure (peak positive LV dP.dt" 1 ) and mean aortic pressure. Cardiac output was determined by the thermodilution method (cardiac output computer 9520 A, Edwards Laboratory, Irvine, CA, U.S.A.). The cardiac index was calculated as cardiac output over the body-surface area. Systemic vascular resistance (UI) was calculated as the difference between mean arterial and mean right atrial pressures divided by the cardiac index.
To obtain coronary sinus blood samples, a N° 7 Fr NIH catheter was inserted into the femoral artery and positioned in the coronary sinus.
DETERMINATION OF PLASMA CATECHOLAMINE AND NPY CONCENTRATIONS
To determine NE, E and NPY plasma concentrations, samples were drawn from the femoral artery (through the femoral sheath) and from the coronary sinus.
NOREPINEPHRINE AND EPINEPHRINE
Plasma epinephrine and norepinephrine were determined in duplicate for each sample by a double-isotope radioenzymatic assay 1161 . In our laboratory, the assay was linear for norepinephrine between 0 and 59-1 nmol. I" 1 and between 0 and 29-4 mmol. 1"' for epinephrine. The sensitivity of the assay was 0-15 nmol. I" 1 for norepinephrine and epinephrine. Intra-assay coefficient of variation was 8% and inter-assay coefficient of variation was 12%.
NPY
Blood samples were collected in 75 g. I"
1 EDTA, immediately centrifuged, and the plasma stored at -20 °C. Two monoclonal NPY antibodies (Mabs: NPY02 and NPY05) were produced and used for development of an immunoradiometric assay (IRMA) for hNPY. This technique has been described previously'' 7 '. In brief, the affinity constants and the difference in the epitope binding regions of NPY02 and NPY05 allowed the development of an IRMA for hNPY determination. The use of NPY02 as the capture antibody and NPY05 as the indicator led to the best results. The standard curves were generated using hNPY diluted in NPY-free plasma. The sensitivity, i.e. the hNPY concentration resulting in an increase in counts per min bound that was 3 SD higher than the mean of the binding in 12 replicates of hNPY-free plasma, was 0-5 pmol. 1"'. Values less than 0-5 pmol. I" 1 were assigned this value. The mean plasma NPY concentration in normal subjects was found to be 2-4 ±2-7 pmol. 1~" in a previous study. Plasma NPY was undetectable (<0-5 pmol. I" 1 ) in 67% of these subjects. The 95th percentile value in the normal group was 7-5pmol. 1"', and this value was defined as the upper limit of the normal range Infusions were given at a constant rate using an infusion pump (Vial-Medical, Grenoble, France).
Catecholamine and NPY concentrations were obtained at the maximal dobutamine infusion rate, both at the peripheral and coronary sinus levels. The NPY concentration was also measured from a new sample drawn 10 min after the end of the intracoronary dobutamine infusion.
Statistical analysis
All data were expressed as the mean ± the standard deviation. Paired t-tests were used to compare different variable changes in patients before and during dobutamine infusion. Linear regression analysis was used to assess the relationship between two parameters. Table 1 summarizes haemodynamic measurements in all 18 patients at baseline and at maximal dobutamine infusion rate. Cardiac index and peak positive left ventricular dP.dt" 1 increased by 28 and 42% (/><001) respectively. Left ventricular end-diastolic pressure and systemic vascular resistance decreased by 42 and 18% (/ > <001) respectively. Heart rate and mean arterial pressure did not change.
Results

HAEMODYNAMIC PARAMETERS
PLASMA CATECHOLAMINE AND NPY CONCENTRATIONS
At baseline. In the femoral artery, NE and E concentrations were 6-48+ 4-5 nmol. 1~' and 104± 0-74nmol. 1~' respectively. NPY concentration was 2-15+ 0-97pmol. 1~'. In the coronary sinus, NE concentration was 10-78 ±5-42 nmol. I" 1 and NPY concentration was 1-97 + 0-63 pmol. I" 1 . At maximal dobutamine infusion rate. In the femoral artery (Fig. 1) , NE concentration decreased to 4-82 ± 2-69 nmol. I" 1 (/><0-001) while E concentration remained unchanged: 0-99±0-61 nmol. I" 1 . NPY concentration did not change: 2-4±0-99 pmol. 1~'. In the coronary sinus, NE (10-13±6-79 nmol. I" 1 ) and NPY (214+.0-9 pmol. 1"') concentrations remained unchanged.
Ten minutes after the end of the dobutamine infusion, while haemodynamic values returned to baseline, NPY concentration, 2-58±0-34pmol. 1~' in the femoral artery, was the same as the baseline value.
RELATIONSHIP BETWEEN HORMONAL DOSAGES AND HAEMODYNAMIC PARAMETERS
NE was negatively correlated with LVEF (r= -0-61, P<00\), cardiac index (r=-0-54, P<005) and with the net increase in LV dP. dt~' during the dobutamine infusion (AdP.dt" 1 ) (r=-0-5, P<005), while it was positively correlated with LV end-diastolic pressure (r = 0-48, P<005) (Fig. 2) . E concentration was not correlated with any haemodynamic variable. No correlation was found between NPY and haemodynamic parameters.
Discussion
The present study examined the relationship between NPY concentrations, catecholamine concentrations and haemodynamics both at baseline and during haemodynamic improvement, which decreased plasma peripheral norepinephrine concentration in patients with congestive heart failure. At baseline, peripheral norepinephrine concentrations were elevated, while NPY concentrations did not differ from those found in patients without heart failure. When the haemodynamic situation improved, norepinephrine concentration decreased in the femoral artery, while NPY concentration did not change. Only norepinephrine concentrations were found to be correlated with haemodynamic parameters.
NPY has been recently identified and found to be widely distributed throughout the central and peripheral nervous system of a variety of mammals including humans . Congestive heart failure is a particular state of activation of the sympathetic nervous system. Indeed, congestive heart failure is characterized by high levels of circulating norepinephrine which are released from terminal sympathetic nerves and it is generally agreed that norepinephrine venous plasma concentrations provide a useful index of average sympathetic nervous activity' 27 -28 '. High catecholamine levels have been shown to be harmful to failing hearts, and recently it has been speculated that NPY could have a detrimental effect on the pathogenesis of heart failure, due to its vasoconstrictor and negative inotropic properties. Using a radioimmunoassay technique, Maisel et a/.' 13 ' found that NPY concentrations were significantly higher in patients with congestive heart failure than in controls. However, while there was no correlation between the level of circulating norepinephrine and NPY concentrations in patients with congestive heart failure, this correlation was present in normal subjects, as reported in other studies' 24 " 251 . During exercise, norepinephrine concentration increased both in patients with congestive heart failure and in normal subjects, while a significant increase in NPY concentration occurred only in the latter. More recently, an increased NPY plasma concentration was observed in coronary care patients with clinical evidence of congestive heart failure 1 ' 4 '. Only acute heart failure was considered and only 25% of these patients had an increase in circulating NPY concentration. In these studies, even if the systemic plasma NPY concentration was significantly higher than in normal subjects, it was not sufficiently high to induce any systemic effect or direct cardiac action.
In the present study, all patients had a chronic stable heart failure. Although norepinephrine concentration was high, NPY concentration was the same as in controls'
171
. This finding was unexpected in this particular case of chronic activation of the sympathetic system, NPY being supposedly released into the circulation upon sympathetic stimulation. These results differ from those obtained by Maisel et a/.' 13 ' Reasons for these differences may be due either to a different patient population, with higher catecholamine concentrations in our study, or to different NPY dosage techniques. In the present study, NPY was measured by a radioimmunometric technique which provided a high specificity for mature hNPY based on epitope recognition and related peptide assay results. This technique was performed initially to assess neuroendocrine tumours and good reproducibility and specificity was observed 1 ' 7 '. The discrepancy observed in our population of stable chronic heart failure patients, at the peripheral level, between high norepinephrine concentrations and rather normal NPY concentrations may result from differences of availability of norepinephrine and NPY at nerve endings. Being a peptide, released NPY is, after synthesis in the body cell, resupplied to nerve endings by axonal transport' 23 -291 . This characteristic is likely to limit the amount of NPY available for terminal release when compared with norepinephrine which is stored in nerve endings and obtained from both local synthesis and reuptake. This could explain the lack of increased NPY concentration. A major point of this and Maisel el a/.'s study is the lack of NPY variation during sympathetic tone changes. Our data demonstrated a decrease in norepinephrine concentration, but not in NPY when sympathetic tone decreased. This could not be attributed to a longer NPY half-life since, lOmin after the end of the dobutamine infusion, NPY concentration remained unchanged' 3 ' 1 . This suggests that the interaction between norepinephrine and NPY is complex, and that their release from nerve endings is not closely correlated. It has been shown previously that the heart contains large amounts of NPY. In our study, NPY coronary sinus concentration did not differ from peripheral concentration. This suggests that in patients with heart failure, NPY concentation in the coronary circulation is not elevated enough to induce any effect on cardiac contractility and coronary vascular tone. Additionally, this result is consistent with the data of Anderson et al. who showed that, when measured in ventricles of patients undergoing cardiac transplantation, NPY myocardial concentration is low when compared to normal hearts' 301 .
In conclusion, the present data show that in patients with stable congestive heart failure, peripheral NPY concentrations are too low to induce any deleterious effect directly on vascular tone or cardiac contractility. A local role of NPY in neurotransmission may not, however, be ruled out in the pathogenesis of congestive heart failure.
